These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31827111)

  • 1. CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.
    Huizing FJ; Garousi J; Lok J; Franssen G; Hoeben BAW; Frejd FY; Boerman OC; Bussink J; Tolmachev V; Heskamp S
    Sci Rep; 2019 Dec; 9(1):18898. PubMed ID: 31827111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
    Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
    Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical validation of
    Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
    Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models.
    Huizing FJ; Hoeben BAW; Lok J; Boerman OC; Heskamp S; Bussink J
    Phys Imaging Radiat Oncol; 2021 Jul; 19():145-150. PubMed ID: 34485720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
    Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
    Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells.
    van Lith SAM; Huizing FJ; Franssen GM; Hoeben BAW; Lok J; Doulkeridou S; Boerman OC; Gotthardt M; van Bergen En Henegouwen PMP; Bussink J; Heskamp S
    Mol Pharm; 2022 Oct; 19(10):3511-3520. PubMed ID: 35044182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
    Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
    Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
    Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines.
    Troost EG; Bussink J; Kaanders JH; van Eerd J; Peters JP; Rijken PF; Boerman OC; van der Kogel AJ
    Radiother Oncol; 2005 Aug; 76(2):194-9. PubMed ID: 16024110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
    Tafreshi NK; Lloyd MC; Proemsey JB; Bui MM; Kim J; Gillies RJ; Morse DL
    Mol Imaging Biol; 2016 Apr; 18(2):219-31. PubMed ID: 26276155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.
    Garousi J; Honarvar H; Andersson KG; Mitran B; Orlova A; Buijs J; Löfblom J; Frejd FY; Tolmachev V
    Mol Pharm; 2016 Nov; 13(11):3676-3687. PubMed ID: 27529191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CAIX with [
    Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
    Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
    Carlin S; Khan N; Ku T; Longo VA; Larson SM; Smith-Jones PM
    PLoS One; 2010 May; 5(5):e10857. PubMed ID: 20523727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
    van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
    van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models.
    Boreel DF; Span PN; Kip A; Boswinkel M; Peters JPW; Adema GJ; Bussink J; Heskamp S
    Mol Pharm; 2023 Apr; 20(4):2245-2255. PubMed ID: 36882391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.